Overview

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Status:
Terminated
Trial end date:
2011-05-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Genentech, Inc.
Treatments:
Erlotinib Hydrochloride
Fluorouracil
Leucovorin
Oxaliplatin